Map Key
Generic Enzyme
Generic kinase
Protein kinase
Lipid kinase
Generic phosphatase
Protein phosphatase
Lipid phosphatase
Generic phospholipase
Generic protease
RAS - superfamily
G beta/gamma
Regulators (GDI, GAP, GEF)
Generic channel
Ligand-gated channel
Voltage-gated channel
Normal process
Pathological process
Positive effect
Negative effect
Unspecified effect
Technical link
Disrupts in disease
Emerges in disease
Enhances in disease
Weakens in disease
Organsim specific interaction

Generic binding protein
Receptor ligand
Cell membrane glycoprotein
Transcription factor
Inorganic ion
Predicted metabolite or user's structure
Generic receptor
Receptors with enzyme activity

Normal process
Pathological process
Covalent modifications
Transcription regulation
MicroRNA binding
Influence on expression
Unspecified interactions
Pharmacological effect
Toxic effect
Group relation
Complex subunit
Similarity reaction
A complex or a group
Organism specific object

Development TGF-beta receptor signaling

Log In to Post A Comment

Development TGF-beta receptor signaling

TGF-beta receptor signaling

Transforming growth factor beta ( TGF-beta ) signaling controls diversecellular processes, including cell proliferation, differentiation, adhesion and migration[1], [2], [3].

TGF-beta 1 initiates signaling by binding to and bringing together type I andtype II receptor serine/threonine kinases ( TGF-beta receptor type I and II) on the cell surface. This allows TGF-beta receptor type II to phosphorylate theTGF-beta receptor type I kinase domain. TGF-beta receptor type I then propagatesthe signal through phosphorylation of the SMAD family member ( SMAD ) proteins[2], [3]. The recognition of SMAD s by TGF-betareceptor type I may be facilitated by auxiliary protein Zinc finger FYVE domaincontaining 9 ( SARA ) [2]. SMAD2 and SMAD3 proteinsform hetero-oligomeric complexes with SMAD4. These SMAD2/ SMAD4and SMAD3/ SMAD4 complexes translocate to the nucleus and, depending onthe cell type and their interactions with coactivators or corepressors, function astranscriptional modulators [4], [3]. SMAD3 translocationto the nucleus depends on binding of Importin (karyopherin)-beta [5].Transcription mediated by SMAD2 or SMAD3 is enhanced by CREB bindingprotein ( CBP )/E1A binding protein p300 ( p300 ) [6], [7]. SMAD s can bind DNA directly with low affinity and specificity and thusrely on interactions with other DNA-binding proteins to target specific genes fortranscriptional regulation, for example Forkhead box H1 ( FAST-1/2 ) [8]. V-ski sarcoma viral oncogene homolog ( Ski ) and SKI-like oncogene (SnoN ) modulate the nuclear activity of SMAD and function as corepressorsantagonize TGF-beta signaling [8], [4]. SMAD3-mediated Anaphase-promoting complex with Fizzy/cell division cycle 20 related 1 (APC/hCDH1 complex ) activation leads to degradation of SnoN [9]. YY1 transcription factor ( YY1 ) as a SMAD -interactingnegatively regulates TGF-beta signaling [10].

SMAD7 inhibits TGF-beta receptor type I [3] via competitionwith SMAD3 or SMAD2 for binding. SMAD7 interaction leads to theubiquitination and degradation of the receptors with the help SMAD specific E3 ubiquitinprotein ligase ( SMURF ). TGF-beta/ SMAD7/ SMURF complex isrouted via Caveolin -rich membrane structures and internalized via Caveolin-positive vesicles toward the proteasome for degradation. FK506 binding protein 1A 12kDa( FKBP12 ) inhibits TGF-beta signaling by binding to the unphosphorylated GSregions of TGF-beta receptor type I. This interaction locks the kinase catalyticcenter of the TGF-beta receptor type I in an unproductive conformation [4], [2]. TGF-beta induces transcription of the humanSMAD7 gene through activation of SMAD3 [11], and transcriptionfactor Ets variant gene 1 ( ER81 ) [12]. Kruppel-like factor 10 (TIEG ) represses SMAD7 gene [13].

SMAD s functionally cooperate with Sp1 transcription factor ( SP1 ) toactivate the Cyclin-dependent kinase inhibitor 1A ( p21 ) promoter [14], Cyclin-dependent kinase inhibitor 2B ( p15 ) [15] (cellcycle regulation [16]), Serpin peptidase inhibitor clade E member 1 (PAI1 ) [17] (regulation of extracellular matrix [16]).

TGF-beta 1 activates p38 MAPK via Mitogen-activated protein kinasekinase kinase 7 interacting protein 1 ( TAB1 ) [18] or SMAD7[19]/ Mitogen-activated protein kinase kinase kinase 7 ( TAK1(MAP3K7))/ Mitogen-activated protein kinase kinase 3 ( MEK3(MAP2K3) ). TGF-beta 1activates, via SMAD3 and SMAD4, expression of Growth arrest andDNA-damage-inducible beta ( GADD45 beta ) that, possibly via Mitogen-activatedprotein kinase kinase kinase 4 ( MEKK4(MAP3K4) ) activates Mitogen-activatedprotein kinase kinase 6 ( MEK6(MAP2K6) ) and then p38 MAPK [20]. TGF-beta activates, in p38 MAPK -dependent manner, Antigenidentified by monoclonal antibody AJ9 ( MSK1 ) activation [21], whichis known to phosphorylate TGF-inducible ER81 [22], [12].ER81 controls SMAD7 expression and V-erb-b2 erythroblastic leukemia viraloncogene homolog 2 neuro/glioblastoma derived oncogene homolog ( ErbB2 ), which isalso involved in SMAD7 expression regulation [12].

TGF-beta receptor directly bind SHC transforming protein 1 ( Shc ) andvia possibly V-Ha-ras Harvey rat sarcoma viral oncogene homolog ( H-Ras )/V-raf-1 murine leukemia viral oncogene homolog 1 ( c-Raf-1 )/ mitogen-activatedprotein kinase kinase 1 and 2 ( MEK1 and MEK2 ) activates Mitogen-activatedprotein kinase 3 and 1 ( ERK1/2 ). This can lead for example toepithelial-to-mesenchymal transition [23], [24], [25]. ERK activates ELK1 member of ETS oncogene family ( Elk-1 ).Elk-1 transcriptionally activates p15 expression [26].

TGF-beta 1 via TAK1(MAP3K7)/ Nuclear factor NFkappaB inhibitor kinases( IKK ) inhibition of Nuclear factor of kappa light polypeptide gene enhancer inB-cells inhibitor alpha ( NFKBIA ) activate Nuclear factor kappa B ( NF-kB). As a result of NF-kB activation, NFKBIA mRNA and protein levels areincreased leading to post-repression of NF-kB and induction of cell death [27].